We kick off with a series of changes on the Board of Directors at Novartis.
Clockwise from top-left we have Dr. Joerg Reinhardt, who will become Chairman as of 1 August, and three new board members Dr. Verena Briner, William Winters and Charles Sawyer.
Reinhardt leaves his position as Chairman of the Board of Management at Bayer to return to Novartis, a company he has a long history with having worked at a Senior level for Sandoz Pharma before the merger which formed Novartis in 1996.
Reinhardt replaces Dr. Daniel Vasella who has been either CEO or Chairman of the Board at Novartis for the last 17 years.
Dr. Briner is Professor of Internal Medicine at the University of Basel and Chief Medical Officer of Medicine of the Lucerne Cantonal Hospital, Switzerland.
Winters is CEO and Chairman of Renshaw Bay, London, an alternative asset management and advisory company.
Sawyers is Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center in New York and Professor of Medicine and of Cell and Developmental Biology at the Graduate School of Medical Sciences at Weill-Cornell University.
Having recently been presented the National Medal of Innovation and Technology from President Obama, MIT Professor Robert Langer has joined the Nanobiosym Scientific Advisory Board.
Langer has been an illustrious force in the biotech and drug delivery and has recently spoken with in-Pharmatechnologist.com about the industry and his award.
Nanobiosym Chairman and CEO, Dr. Anita Goel said: “Dr. Langer has been pioneering the precision delivery of drugs and novel therapeutics and we at Nanobiosym have been developing mobile platforms that quantify molecular fingerprints in real time. In collaboration with forward-thinking pharmaceutical companies, we are developing companion nanodiagnostics that will enable novel medicines and therapies to reach patients fast.”
Biopharmaceutical Company Chimerix has announced that Dr. Ernest Mario will become Chairman of its Board of Directors.
Currently Chairman and CEO of Capnia, a privately held pharmaceutical company, Mario has previously served as Chairman and CEO of Reliant Pharmaceuticals up until its acquisition by GlaxoSmithKline in 2007.
“Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms,” said Chimerix President and CEO, Kenneth I. Moch. “His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through Phase 3 clinical development and commercial launch."
Ipsen, a global specialty-driven pharmaceutical company, has announced the appointment of Christel Bories as Deputy Chief Executive Officer, responsible for accelerating the execution of the Group’s strategy.
Coming from a mainly industrial background, Bories is presently Chairperson of the Strategy Committee of Legrand and a member of the Board of Directors of Smurfit Kappa.
Marc de Garidel, Chairman and CEO of Ipsen, said of Bories: “She will provide a new perspective on our activities and the Group will benefit from her extensive experience both in France and internationally. In her various positions, Christel demonstrated strong know-how and proven effectiveness in operational management. Christel shares our values and her expertise will be valuable to accelerate Ipsen’s development.”
Warren Lammert has joined the Board of Advisors at discoverer of therapies for neurological diseases, IntelliMedix.
Lammert is the Chairman and co-founder of the Epilepsy Therapy Project and Epilepsy.com and is also a board member for FACES (Finding a Cure for Epilepsy and Seizures) at New York University.
Daniel Fischer, President and CEO of Intellimedix said: “Warren brings an impressive track record accelerating innovation for new therapies in the field of epilepsy. Warren's drive, passion and proven business acumen will be a great contribution to the Intellimedix team.”
Rafael V. Andino has been named to the position of Vice President, Product Development at Clearside Biomedical.
Andino has over 25 years of experience in the pharmaceutical and medical device industry and comes to Clearside from Bard Medical where he served as Director of R&D.
Daniel White, President and CEO said: “Rafael’s product development and leadership experience and his proven ability to bring new products to market will be an invaluable asset to us, and he will play an integral role in the leadership team we are building at Clearside Biomedical.”